ABBOTT LABORATORIES

ABTUnited States

79 filed reports · 480 financial concepts · 42 earnings calls · 7 media appearances

Latest figures

Group totals as stated in the company’s own filed reports, each with a link to its report. The change is against the same period a year earlier.

Latest fiscal year

Revenue

$44.3B

FY2025 · to Dec 31, 2025

up +5.7% vs $42B

10-K

Net income

$6.52B

FY2025 · to Dec 31, 2025

down −51.3% vs $13.4B

10-K

Operating income

$8.05B

FY2025 · to Dec 31, 2025

up +18.0% vs $6.83B

10-K

Latest quarter

Revenue

$13B

Q3 FY2026 · to Sep 30, 2026

up +14.5% vs $11.4B

10-Q

Net income

$920M

Q3 FY2026 · to Sep 30, 2026

down −44.0% vs $1.64B

10-Q

Operating income

$1.36B

Q3 FY2026 · to Sep 30, 2026

down −34.0% vs $2.06B

10-Q

Filed reports

79 reports · Jun 2016 to Sep 2026

Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 17 operating metrics, 196 guidance figures, 12 earnings-release figures, 159 commentary passages.

Report typeReportsFactsPeriods
Current · 8-KSEC EDGAR35195Jun 2018 to Sep 2026
Quarterly · 10-QSEC EDGAR337,061Jun 2016 to Sep 2026
Annual · 10-KSEC EDGAR116,422Dec 2016 to Dec 2025

Documents

PeriodTypePeriod endPublishedFactsSource
FY2026 Q310-Q2026-09-302026-11-04483Open
FY2026 Q38-K2026-09-302026-10-2113Open
FY2026 Q210-Q2026-06-302026-07-28353Open
FY2026 Q28-K2026-06-302026-07-166Open
FY2026 Q28-K2026-06-302026-07-165Open
FY2026 Q110-Q2026-03-312026-04-2913Open
FY2026 Q110-Q2026-03-312026-04-29352Open
FY2026 Q18-K2026-03-312026-04-165Open
FY2026 Q18-K2026-03-312026-04-166Open
FY202510-K2025-12-312026-02-201,320Open
FY202510-K2025-12-312026-02-2013Open
FY2025 Q48-K2025-12-312026-01-226Open

Financial data

480 concepts · 13,678 facts

Each concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.

Financial445 concepts · 9,300 facts · Dec 2014 to Sep 2026

  • Amortization of intangible assets60 · Dec 2014 to Sep 2026
  • Cash and cash equivalents at carrying value59 · Dec 2014 to Sep 2026
  • Comprehensive income net of tax59 · Dec 2014 to Sep 2026
  • Costs and expenses59 · Dec 2014 to Sep 2026
  • Foreign currency transaction gain loss before tax59 · Dec 2014 to Sep 2026
  • Income loss from continuing operations before income taxes extraordinary items noncontrolling interest59 · Dec 2014 to Sep 2026
  • Income tax expense benefit59 · Dec 2014 to Sep 2026
  • Investment income interest59 · Dec 2014 to Sep 2026
  • Net income loss59 · Dec 2014 to Sep 2026
  • Net income loss available to common stockholders basic59 · Dec 2014 to Sep 2026
  • Operating income loss59 · Dec 2014 to Sep 2026
  • Other comprehensive income loss net of tax portion attributable to parent59 · Dec 2014 to Sep 2026
  • Other comprehensive income loss pension and other postretirement benefit plans tax59 · Dec 2014 to Sep 2026
  • Other nonoperating income expense59 · Dec 2014 to Sep 2026
  • Revenue59 · Dec 2014 to Sep 2026
  • Selling general and administrative expense59 · Dec 2014 to Sep 2026
  • Depreciation57 · Dec 2014 to Sep 2026
  • Increase decrease in accounts receivable57 · Dec 2014 to Sep 2026
  • Increase decrease in inventories57 · Dec 2014 to Sep 2026
  • Net cash provided by used in financing activities57 · Dec 2014 to Sep 2026
  • Net cash provided by used in investing activities57 · Dec 2014 to Sep 2026
  • Net cash provided by used in operating activities57 · Dec 2014 to Sep 2026
  • Payments for proceeds from other investing activities57 · Dec 2014 to Sep 2026
  • Payments for repurchase of common stock57 · Dec 2014 to Sep 2026

Segment20 concepts · 3,930 facts · Dec 2014 to Sep 2026

  • Revenue3,010 · Dec 2014 to Sep 2026
  • Operating income loss241 · Dec 2014 to Sep 2026
  • Goodwill156 · Jun 2016 to Mar 2026
  • Depreciation102 · Dec 2014 to Sep 2026
  • Total Assets73 · Dec 2015 to Mar 2026
  • Segment expenditure addition to long lived assets64 · Dec 2021 to Sep 2026
  • Cost of goods and services sold (US GAAP)60 · Dec 2022 to Sep 2026
  • Research and development expense60 · Dec 2022 to Sep 2026
  • Selling general and administrative expense60 · Dec 2022 to Sep 2026
  • Property plant and equipment additions29 · Dec 2017 to Dec 2022
  • Payments to acquire property plant and equipment20 · Dec 2015 to Dec 2018
  • Impairment of intangible assets indefinitelived excluding goodwill17 · Mar 2016 to Dec 2024
  • Payments to acquire productive assets15 · Dec 2014 to Dec 2016
  • Impairment of intangible assets finitelived7 · Sep 2020 to Dec 2024
  • Revenue (excluding assessed tax)6 · Dec 2019 to Dec 2021
  • Inventory recall expense3 · Mar 2022 to Sep 2022
  • Disposal group not discontinued operation gain loss on disposal2 · Jun 2024 to Dec 2024
  • Established Pharmaceuticals2 · Jun 2024 to Dec 2024
  • Indefinite lived intangible assets period increase decrease2 · Dec 2024 to Dec 2025
  • Revenue from contracts with customers (excluding tax)1 · Dec 2017

Geography5 concepts · 253 facts · Dec 2014 to Sep 2026

  • Revenue242 · Dec 2014 to Sep 2026
  • Foreign currency transaction loss before tax6 · Mar 2016 to Dec 2016
  • Effect of exchange rate on cash and cash equivalents3 · Mar 2016 to Sep 2016
  • Unrecognized tax benefits increases resulting from prior period tax positions1 · Dec 2021
  • Venezuela1 · Sep 2016

Guidance8 concepts · 178 facts · Jul 2018 to Oct 2026

  • EPS (Diluted) Guidance90 · Jul 2018 to Jul 2026
  • EPS (Diluted) Guidance (Adjusted (non-GAAP))48 · Jul 2018 to Oct 2026
  • Revenue Growth Guidance22 · Jan 2023 to Jul 2026
  • Revenue Growth Guidance (Organic)8 · Jan 2019 to Apr 2024
  • Operating Margin Guidance6 · Jan 2025 to Jul 2025
  • Revenue Growth Guidance (Comparable)2 · Oct 2026
  • EPS (Diluted) Growth Guidance1 · Jan 2021
  • EPS (Diluted) Growth Guidance (Adjusted (non-GAAP))1 · Jan 2021

KPI2 concepts · 17 facts · Sep 2025 to Sep 2026

  • Comparable Sales Growth15 · Mar 2026 to Sep 2026
  • Interest expense, net2 · Sep 2025 to Sep 2026

Segments

4,183 facts

Figures broken down by business line, region, product or another axis the company reports on.

Subsegments20 members · 2,282 facts

  • Electrophysiology163 · Mar 2017 to Sep 2026
  • Heart Failure163 · Mar 2017 to Sep 2026
  • Neuromodulation163 · Mar 2017 to Sep 2026
  • Rhythm Management163 · Mar 2017 to Sep 2026
  • Structural Heart163 · Mar 2017 to Sep 2026
  • Adult Nutritionals148 · Mar 2017 to Sep 2026
  • Core Laboratory148 · Mar 2017 to Sep 2026
  • Pediatric Nutritionals148 · Mar 2017 to Sep 2026
  • Molecular139 · Mar 2017 to Dec 2025
  • Point Of Care139 · Mar 2017 to Dec 2025
  • Key Emerging Markets127 · Mar 2017 to Sep 2026
  • Rapid Diagnostics125 · Dec 2017 to Dec 2025
  • Diabetes Care120 · Dec 2017 to Sep 2026
  • Other Emerging Markets87 · Dec 2020 to Sep 2026
  • Vascular81 · Dec 2020 to Sep 2026
  • Other69 · Mar 2017 to Mar 2022
  • Cardiovascular And Neuromodulation Products57 · Dec 2017 to Jun 2022
  • Vascular Products43 · Mar 2017 to Sep 2019
  • Cancer Diagnostics18 · Mar 2025 to Sep 2026
  • Rapid And Molecular18 · Mar 2025 to Sep 2026

Statement business segments14 members · 1,648 facts

  • Diagnostic Products333 · Dec 2014 to Sep 2026
  • Nutritional Products318 · Dec 2014 to Sep 2026
  • Established Pharmaceutical Products301 · Dec 2014 to Sep 2026
  • Medical Devices264 · Dec 2017 to Sep 2026
  • All Other Segments100 · Dec 2014 to Mar 2022
  • Cardiovascular And Neuromodulation Products91 · Dec 2014 to Sep 2019
  • Diagnostic products56 · Dec 2015 to Mar 2026
  • Established pharmaceutical products56 · Dec 2015 to Mar 2026
  • Nutritional products56 · Dec 2015 to Mar 2026
  • Medical devices39 · Dec 2018 to Mar 2026
  • Cardiovascular and neuromodulation products19 · Dec 2015 to Sep 2019
  • All other segments6 · Dec 2019 to Dec 2021
  • Non Reportable5 · Mar 2016 to Dec 2016
  • Non reportable segment4 · Dec 2015 to Dec 2018

Statement geographicalsrt:StatementGeographicalAxis13 members · 177 facts

  • Non Us49 · Mar 2017 to Sep 2026
  • US49 · Dec 2016 to Sep 2026
  • CH10 · Dec 2016 to Dec 2025
  • CN10 · Dec 2016 to Dec 2025
  • DE10 · Dec 2016 to Dec 2025
  • IN10 · Dec 2016 to Dec 2025
  • JP10 · Dec 2016 to Dec 2025
  • NL9 · Dec 2016 to Dec 2024
  • All Other Countries6 · Dec 2020 to Dec 2025
  • Other Countries6 · Dec 2016 to Dec 2021
  • CA4 · Dec 2019 to Dec 2022
  • GB3 · Dec 2023 to Dec 2025
  • VE1 · Dec 2016

Statement geographicalus-gaap:StatementGeographicalAxis18 members · 76 facts

  • VE9 · Mar 2016 to Dec 2016
  • US6 · Dec 2014 to Mar 2018
  • BR4 · Dec 2014 to Dec 2017
  • CA4 · Dec 2014 to Dec 2017
  • CH4 · Dec 2014 to Dec 2017
  • CN4 · Dec 2014 to Dec 2017
  • CO4 · Dec 2014 to Dec 2017
  • DE4 · Dec 2014 to Dec 2017
  • GB4 · Dec 2014 to Dec 2017
  • IN4 · Dec 2014 to Dec 2017
  • IT4 · Dec 2014 to Dec 2017
  • JP4 · Dec 2014 to Dec 2017
  • NL4 · Dec 2014 to Dec 2017
  • Other Countries4 · Dec 2014 to Dec 2017
  • RU4 · Dec 2014 to Dec 2017
  • VN4 · Dec 2014 to Dec 2017
  • FR3 · Dec 2015 to Dec 2017
  • Non Us2 · Mar 2017 to Mar 2018

Text from filings

Management commentary and risk factors, extracted from SEC filings only.

  • Earnings-release commentary118 claims from 9 reports · Sep 2024 to Sep 2026
  • Management discussion (MD&A) commentary270 claims from 9 reports · Sep 2024 to Sep 2026
  • Risk-factor changes23 claims from 6 reports · Dec 2017 to Dec 2025
  • Risk factors167 risks from 9 annual reports · 2016 to 2025

Earnings calls

42 calls · Jul 2016 to Oct 2026

Transcripts with management claims and analyst questions, one per fiscal period.

  • FY2026 Q32026-10-21
  • FY2026 Q22026-07-16
  • FY2026 Q12026-04-16
  • FY2025 Q42026-01-22
  • FY2025 Q32025-10-15
  • FY2025 Q22025-07-17
  • FY2025 Q12025-04-16
  • FY2024 Q42025-01-22
  • FY2024 Q32024-10-16
  • FY2024 Q22024-07-18
  • FY2024 Q12024-04-17
  • FY2023 Q42024-01-23
  • FY2023 Q32023-10-17
  • FY2023 Q22023-07-19
  • FY2023 Q12023-04-18
  • FY2022 Q42023-01-24

Executive media

7 appearances

Podcasts, interviews and conference appearances by the company's executives, with their claims.

  • TV interviews4 · Oct 2021 to Jul 2025
  • Other appearances3 · Mar 2021 to Aug 2025

Ask about this company in your AI model

Connect FactIQ to Claude, ChatGPT or another AI model (how to install), then paste this prompt.

Use FactIQ to get the revenue, net income and operating income of ABBOTT LABORATORIES (ABT) from its filed reports, for the last five fiscal years and the latest quarter or half year. Link each figure to its filing, and chart the trend.

Works once FactIQ is connected

Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Nov 20, 2026) and refreshed every few hours.